Literature DB >> 22505582

Impaired calcium calmodulin kinase signaling and muscle adaptation response in the absence of calpain 3.

I Kramerova1, E Kudryashova, N Ermolova, A Saenz, O Jaka, A López de Munain, M J Spencer.   

Abstract

Mutations in the non-lysosomal, cysteine protease calpain 3 (CAPN3) result in the disease limb girdle muscular dystrophy type 2A (LGMD2A). CAPN3 is localized to several subcellular compartments, including triads, where it plays a structural, rather than a proteolytic, role. In the absence of CAPN3, several triad components are reduced, including the major Ca(2+) release channel, ryanodine receptor (RyR). Furthermore, Ca(2+) release upon excitation is impaired in the absence of CAPN3. In the present study, we show that Ca-calmodulin protein kinase II (CaMKII) signaling is compromised in CAPN3 knockout (C3KO) mice. The CaMK pathway has been previously implicated in promoting the slow skeletal muscle phenotype. As expected, the decrease in CaMKII signaling that was observed in the absence of CAPN3 is associated with a reduction in the slow versus fast muscle fiber phenotype. We show that muscles of WT mice subjected to exercise training activate the CaMKII signaling pathway and increase expression of the slow form of myosin; however, muscles of C3KO mice do not exhibit these adaptive changes to exercise. These data strongly suggest that skeletal muscle's adaptive response to functional demand is compromised in the absence of CAPN3. In agreement with our mouse studies, RyR levels were also decreased in biopsies from LGMD2A patients. Moreover, we observed a preferential pathological involvement of slow fibers in LGMD2A biopsies. Thus, impaired CaMKII signaling and, as a result, a weakened muscle adaptation response identify a novel mechanism that may underlie LGMD2A and suggest a pharmacological target that should be explored for therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22505582      PMCID: PMC3491917          DOI: 10.1093/hmg/dds144

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  39 in total

Review 1.  Cellular signaling through multifunctional Ca2+/calmodulin-dependent protein kinase II.

Authors:  T R Soderling; B Chang; D Brickey
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

2.  Insertion sequence 1 of muscle-specific calpain, p94, acts as an internal propeptide.

Authors:  Beatriz Garcia Diaz; Tudor Moldoveanu; Michael J Kuiper; Robert L Campbell; Peter L Davies
Journal:  J Biol Chem       Date:  2004-04-08       Impact factor: 5.157

3.  Skeletal muscle Ca(2+)-independent kinase activity increases during either hypertrophy or running.

Authors:  M Flück; M N Waxham; M T Hamilton; F W Booth
Journal:  J Appl Physiol (1985)       Date:  2000-01

4.  CaMKII regulates contraction- but not insulin-induced glucose uptake in mouse skeletal muscle.

Authors:  Carol A Witczak; Niels Jessen; Daniel M Warro; Taro Toyoda; Nobuharu Fujii; Mark E Anderson; Michael F Hirshman; Laurie J Goodyear
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-03-09       Impact factor: 4.310

5.  Calpain 3 gene mutations: genetic and clinico-pathologic findings in limb-girdle muscular dystrophy.

Authors:  J Chae; N Minami; Y Jin; M Nakagawa; K Murayama; F Igarashi; I Nonaka
Journal:  Neuromuscul Disord       Date:  2001-09       Impact factor: 4.296

6.  Studies of the regulatory mechanism of Ca2+/calmodulin-dependent protein kinase II. Mutation of threonine 286 to alanine and aspartate.

Authors:  Y L Fong; W L Taylor; A R Means; T R Soderling
Journal:  J Biol Chem       Date:  1989-10-05       Impact factor: 5.157

7.  Alteration of sarcoplasmic reticulum ca release in skeletal muscle from calpain 3-deficient mice.

Authors:  Govindan Dayanithi; Isabelle Richard; Cédric Viero; Elsa Mazuc; Sylvie Mallie; Jean Valmier; Nathalie Bourg; Muriel Herasse; Isabelle Marty; Gérard Lefranc; Paul Mangeat; Stephen Baghdiguian
Journal:  Int J Cell Biol       Date:  2010-03-14

8.  Mitochondrial abnormalities, energy deficit and oxidative stress are features of calpain 3 deficiency in skeletal muscle.

Authors:  Irina Kramerova; Elena Kudryashova; Benjamin Wu; Sean Germain; Krista Vandenborne; Nadine Romain; Ronald G Haller; M Anthony Verity; Melissa J Spencer
Journal:  Hum Mol Genet       Date:  2009-05-29       Impact factor: 6.150

9.  Targeted inhibition of Ca2+ /calmodulin signaling exacerbates the dystrophic phenotype in mdx mouse muscle.

Authors:  Joe V Chakkalakal; Stephanie A Michel; Eva R Chin; Robin N Michel; Bernard J Jasmin
Journal:  Hum Mol Genet       Date:  2006-03-21       Impact factor: 6.150

10.  Gene expression profiling in limb-girdle muscular dystrophy 2A.

Authors:  Amets Sáenz; Margarita Azpitarte; Rubén Armañanzas; France Leturcq; Ainhoa Alzualde; Iñaki Inza; Federico García-Bragado; Gaspar De la Herran; Julián Corcuera; Ana Cabello; Carmen Navarro; Carolina De la Torre; Eduard Gallardo; Isabel Illa; Adolfo López de Munain
Journal:  PLoS One       Date:  2008-11-18       Impact factor: 3.240

View more
  21 in total

1.  PLEIAD/SIMC1/C5orf25, a novel autolysis regulator for a skeletal-muscle-specific calpain, CAPN3, scaffolds a CAPN3 substrate, CTBP1.

Authors:  Yasuko Ono; Shun-Ichiro Iemura; Stefanie M Novak; Naoko Doi; Fujiko Kitamura; Tohru Natsume; Carol C Gregorio; Hiroyuki Sorimachi
Journal:  J Mol Biol       Date:  2013-05-21       Impact factor: 5.469

2.  Low-frequency stimulation regulates metabolic gene expression in paralyzed muscle.

Authors:  Michael Petrie; Manish Suneja; Richard K Shields
Journal:  J Appl Physiol (1985)       Date:  2015-01-29

3.  C3KO mouse expression analysis: downregulation of the muscular dystrophy Ky protein and alterations in muscle aging.

Authors:  Oihane Jaka; Irina Kramerova; Margarita Azpitarte; Adolfo López de Munain; Melissa Spencer; Amets Sáenz
Journal:  Neurogenetics       Date:  2012-07-22       Impact factor: 2.660

4.  Autolytic activation of calpain 3 proteinase is facilitated by calmodulin protein.

Authors:  Natalia Ermolova; Irina Kramerova; Melissa J Spencer
Journal:  J Biol Chem       Date:  2014-11-11       Impact factor: 5.157

5.  Fnip1 regulates skeletal muscle fiber type specification, fatigue resistance, and susceptibility to muscular dystrophy.

Authors:  Nicholas L Reyes; Glen B Banks; Mark Tsang; Daciana Margineantu; Haiwei Gu; Danijel Djukovic; Jacky Chan; Michelle Torres; H Denny Liggitt; Dinesh K Hirenallur-S; David M Hockenbery; Daniel Raftery; Brian M Iritani
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-29       Impact factor: 11.205

6.  The N- and C-terminal autolytic fragments of CAPN3/p94/calpain-3 restore proteolytic activity by intermolecular complementation.

Authors:  Yasuko Ono; Mayumi Shindo; Naoko Doi; Fujiko Kitamura; Carol C Gregorio; Hiroyuki Sorimachi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

Review 7.  Running forward: new frontiers in endurance exercise biology.

Authors:  Glenn C Rowe; Adeel Safdar; Zolt Arany
Journal:  Circulation       Date:  2014-02-18       Impact factor: 29.690

8.  Failure to up-regulate transcription of genes necessary for muscle adaptation underlies limb girdle muscular dystrophy 2A (calpainopathy).

Authors:  Irina Kramerova; Natalia Ermolova; Ascia Eskin; Andrea Hevener; Oswald Quehenberger; Aaron M Armando; Ronald Haller; Nadine Romain; Stanley F Nelson; Melissa J Spencer
Journal:  Hum Mol Genet       Date:  2016-03-22       Impact factor: 6.150

Review 9.  Molecular and cellular basis of genetically inherited skeletal muscle disorders.

Authors:  James J Dowling; Conrad C Weihl; Melissa J Spencer
Journal:  Nat Rev Mol Cell Biol       Date:  2021-07-13       Impact factor: 94.444

10.  Redox state and mitochondrial respiratory chain function in skeletal muscle of LGMD2A patients.

Authors:  Mats I Nilsson; Lauren G Macneil; Yu Kitaoka; Fatimah Alqarni; Rahul Suri; Mahmood Akhtar; Maria E Haikalis; Pavneet Dhaliwal; Munim Saeed; Mark A Tarnopolsky
Journal:  PLoS One       Date:  2014-07-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.